Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genalyte Inc. is active in the Biotechnology & Pharmaceuticals technology area. The company currently manages 1 pending office action. This matter is assigned to 1 distinct examiner and is located within a distinct art unit. This structure indicates a focused prosecution strategy where all current activity is directed through the point of contact at the patent office. Such a concentrated approach often characterizes portfolios with specific technical goals.
The busiest examiner for the portfolio is MARCSISIN, ELLEN JEAN. This examiner is responsible for the busiest examiner pending office action. Since this workload represents the total pending volume for the company, the prosecution's progress is tied to the findings of this specific individual. For a practitioner, this concentration allows for a streamlined response process. However, it also means the portfolio lacks the examiner diversity found in larger sets of filings. The resolution of this pending matter will be a factor in the company's near-term intellectual property position.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARCSISIN, ELLEN JEAN | 1 | 34.6% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17051278 | METHODS AND COMPOSITIONS FOR POINT OF CARE MEASUREMENT OF THE BIOAVAILABILITY OF THERAPEUTIC BIOLOGICS | MARCSISIN, ELLEN JEAN | 285d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17051278 | METHODS AND COMPOSITIONS FOR POINT OF CARE MEASUREMENT OF THE BIOAVAILABILITY OF THERAPEUTIC BIOLOGICS | MARCSISIN, ELLEN JEAN | 285d overdue |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17051278 | METHODS AND COMPOSITIONS FOR POINT OF CARE MEASUREMENT OF THE BIOAVAILABILITY OF THERAPEUTIC BIOLOGICS | MARCSISIN, ELLEN JEAN | 1677 | §103§112Other | Final Rejection | 285d overdue | Pending | Oct 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenalyte Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ellen Jean Marcsisin has the most, with 1 of Genalyte Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
